Vanda Pharmaceuticals Q3 2026: Loss Beat, Revenue Up 24%

As seen on the 24/7 Wall St. homepage on October 28, 2026.

VNDA Vanda Pharmaceuticals
Q3 2026
EPS
-$0.37
est -$0.68 +45.8%
Revenue
$70M
est $69M +1.0%

Vanda's spending fell for the first time as Phase III work wrapped up, with the loss beating expectations and revenue climbing 24% year over year. Management now guides full-year revenue above $240 million, with the BYSANTI launch and a December 12 PDUFA date for Quimilza still ahead.

Continue ReadingShow less

Vanda Pharmaceuticals posted a third-quarter loss of $0.37 per share, beating expectations, with revenue rising 24% year over year. Roughly $7.0 million of HETLIOZ orders shipped June 29 landed in the quarter, a modest timing lift.

Fanapt drove the growth, generating $38.8 million as total prescriptions rose 25%. HETLIOZ, PONVORY and newly promoted NEREUS added the rest.

Operating expenses fell 18% sequentially as Phase III and launch-preparation spending wound down, and management expects that trend to continue. The raised full-year 2026 revenue outlook now hinges on the BYSANTI launch and a December 12 PDUFA date for Quimilza, under FDA review for generalized pustular psoriasis.

Sponsored

The pipeline carries both opportunity and risk. Positive Phase III results support planned supplemental filings for NEREUS and HETLIOZ, with a formal FDA hearing on HETLIOZ for jet lag disorder set for December 14 through 18. The recent failure of VQW-765 in social anxiety disorder shows how fast pipeline value evaporates.

This quarter marks a return to beating expectations and the narrowest quarterly loss in at least two years. Whether cost discipline and the multi-product launch cadence hold through the December catalysts is what investors are pricing now.

Mentioned: VNDA